Global Idiopathic Pulmonary Fibrosis Market to grow with a CAGR of 5.94%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Idiopathic Pulmonary Fibrosis Market.
According
to TechSci Research report, “Global Idiopathic Pulmonary Fibrosis Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Idiopathic Pulmonary
Fibrosis Market has valued at USD 2.25 billion in 2022 and is anticipated to
witness an impressive growth in the forecast period with a CAGR of 5.94%
through 2028. This can be due to collaborations and partnerships among leading
companies with a diverse approach to merge the expertise of individual companies
and to strengthen their position in the market. Awareness and education play a
crucial role in driving the demand for the Global Idiopathic Pulmonary Fibrosis
(IPF) Market. Increased awareness and education about IPF symptoms and risk
factors can lead to earlier diagnosis. Early diagnosis is associated with
better treatment outcomes, and patients may seek medical attention sooner if
they are aware of the disease. Informed patients are more likely to seek
medical advice and ask healthcare providers about IPF. This can lead to
increased patient demand for diagnostic tests and therapies. Education about
the importance of treatment and adherence to prescribed therapies can lead to
better patient compliance. Patients who understand their condition and
treatment regimens are more likely to follow them closely. Greater awareness
can lead to increased public and private sector funding for IPF research. More
funding supports research initiatives to develop new therapies and diagnostic
tools, driving demand in the research and development sector. Awareness
campaigns often involve patient advocacy groups that work to raise awareness
about IPF. These groups may advocate for better access to care and increased
research funding, which can drive demand for related products and services. Increased
awareness among healthcare providers can lead to more accurate and timely
diagnoses of IPF. This can generate demand for diagnostic tools and
consultations with specialists.
Browse
over XX market data Figures and spread through XX
Pages and an in-depth TOC on " Global Idiopathic Pulmonary Fibrosis Market.”
Idiopathic Pulmonary Fibrosis (IPF) is a
chronic lung disease characterized by the progressive thickening and stiffening
of lung tissues over time. This thickening restricts the lungs' ability to
effectively oxygenate the bloodstream, impacting oxygen delivery to vital
organs, including the brain. IPF leads to the accumulation of scar tissue
(fibrosis) in the lungs, further hampering the efficient transport of oxygen.
This condition primarily affects individuals in the age range of 50 to 70. IPF
is categorized under a group of conditions known as interstitial lung diseases
(ILD), which encompass lung disorders involving inflammation or scarring within
the lung tissue. In May 2023,
Cumberland Pharmaceuticals Inc. announced that the U.S. Food and Drug
Administration (FDA) has granted clearance for the Investigational New Drug
Application (IND) related to a Phase II study focusing on patients with
Idiopathic Pulmonary Fibrosis, which is the most common form of progressive
fibrosing interstitial lung disease. Consequently, Cumberland is set to
initiate its FIGHTING FIBROSIS trial, with plans to enroll 128 patients across
more than 20 leading medical centres in the United States. In this development,
Idiopathic Pulmonary Fibrosis (IPF) emerges as the latest addition to
Cumberland's clinical program, involving their first new chemical entity,
ifetroban – a powerful and selective thromboxane receptor antagonist. The
company has devised a Phase II clinical trial aimed at assessing the safety,
tolerability, and effectiveness of oral ifetroban in patients with IPF. Recent
research has demonstrated ifetroban's ability to both prevent and promote the
resolution of lung fibrosis in various preclinical models.
Healthcare
disparities are a significant challenge in the Global Idiopathic Pulmonary
Fibrosis (IPF) Market. Healthcare disparities refer to differences in
healthcare access, quality of care, and health outcomes among various
population groups. These disparities can impact the diagnosis, treatment, and
overall care of individuals with IPF. Patients from underserved or marginalized
communities may face barriers to accessing healthcare services, leading to
delayed diagnosis and treatment initiation. This delay can impact disease
prognosis. IPF is a complex and rare lung disease that often requires
specialized care from pulmonologists and healthcare centers experienced in
managing the condition. Disparities in access to specialized care can lead to
suboptimal treatment. Geographic disparities can affect access to healthcare
services. Patients in rural or remote areas may have limited access to
healthcare facilities and specialists, impacting their ability to receive
timely and quality care. Socioeconomic disparities, including income,
education, and insurance status, can influence the type and quality of care
received.
Patients
with limited financial resources may face difficulties in accessing expensive
medications and therapies. Racial and ethnic minorities may experience
disparities in IPF care. These disparities can be related to access to care,
cultural factors, and bias within the healthcare system. IPF is more common in men, and gender-related
disparities can affect the care received by female patients. Women with IPF may
face challenges in diagnosis and access to treatment options. Language barriers
can hinder communication between healthcare providers and patients, potentially
leading to misunderstandings about the diagnosis and treatment of IPF.
Global Idiopathic Pulmonary Fibrosis Market is
segmented based on Drug Type, Route of Administration, Distribution Channel, and
by region. Based on the Drug Type, Global Idiopathic
Pulmonary Fibrosis Market is segmented into Pirfenidone, Nintedanib, and others. Nintedanib is a medication
used in the treatment of various pulmonary and fibrotic diseases, with one of
its primary applications being in the management of Idiopathic Pulmonary
Fibrosis (IPF). Nintedanib is approved for the treatment of Idiopathic Pulmonary
Fibrosis (IPF), a progressive lung disease characterized by the scarring of
lung tissue. It is used to slow the progression of the disease. Nintedanib is
classified as a tyrosine kinase inhibitor. It works by blocking specific
signaling pathways that play a role in the formation of fibrotic tissue in the
lungs. By inhibiting these pathways, Nintedanib can help slow down the scarring
process, which is a hallmark of IPF. Nintedanib is used as a disease-modifying
therapy for IPF. It is not a cure, but it can help slow the decline in lung
function and improve the quality of life for individuals with IPF. Nintedanib
is typically taken orally in the form of capsules. The recommended dosage and
treatment duration are determined by a healthcare provider based on the
individual's condition and medical history.
Based on Region, North
America held the largest share in the Global
Idiopathic Pulmonary Fibrosis Market. North America has a relatively
high prevalence of IPF, with a significant number of patients in the region.
This, in turn, creates a substantial market for IPF-related products and
services. The regulatory environment in North America is generally conducive to
the development and marketing of new therapies for rare and serious diseases
like IPF. North America is home to several patient advocacy groups and
organizations dedicated to supporting those with IPF. These groups play a role
in raising awareness, promoting research, and providing resources for patients.
The region hosts research institutions, academic centers, and medical
universities that actively engage in IPF research and collaborate with the
pharmaceutical industry to develop and test new treatments.
Some of the major companies
operating in the Global Idiopathic
Pulmonary Fibrosis Market include:
- Boehringer
Ingelheim
- F.
Hoffmann-La Roche AG
- Cipla
Ltd.
- Shionogi
& Co., Ltd.
- Bristol-Myers
Squibb Co.
- United
Therapeutics
- FibroGen,
Inc.
- Pliant
Therapeutics
- Galecto
Inc.
- CSL
Behring
Download Free Sample Report
Customers can also request
for 10% free customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Idiopathic Pulmonary
Fibrosis treatment. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Idiopathic Pulmonary Fibrosis Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Idiopathic
Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib,
others), By Route of Administration (Parenteral, Oral, Others), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, By Competition Forecast &
Opportunities, 2018-2028F has evaluated the future growth potential
of Global Idiopathic Pulmonary Fibrosis Market and provides statistics &
information on market size, structure, and future market growth. The report
intends to provide innovative market intelligence and help decision makers take
sound investment decisions. Besides, the report also identifies and analyzes
the emerging trends along with essential drivers, challenges, and opportunities
in Global Idiopathic Pulmonary Fibrosis Market.
Contact
Techsci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel:
+13322586602
Email:
[email protected]
Website:
www.techsciresearch.com